0001209191-21-023819.txt : 20210331 0001209191-21-023819.hdr.sgml : 20210331 20210331171131 ACCESSION NUMBER: 0001209191-21-023819 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210330 FILED AS OF DATE: 20210331 DATE AS OF CHANGE: 20210331 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Camardo Daniel A. CENTRAL INDEX KEY: 0001820365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 21794518 MAIL ADDRESS: STREET 1: C/O HORIZON THERAPEUTICS, PLC STREET 2: CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD CITY: DUBLIN STATE: L2 ZIP: D04 C5Y6 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Therapeutics Public Ltd Co CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: Horizon Pharma plc DATE OF NAME CHANGE: 20140919 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-30 0 0001492426 Horizon Therapeutics Public Ltd Co HZNP 0001820365 Camardo Daniel A. C/O HORIZON THERAPEUTICS PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4 IRELAND 0 1 0 0 EVP and President, U.S. Ordinary Shares 2021-03-30 4 S 0 1803 83.58 D 43997 D Ordinary Shares 2021-03-30 4 S 0 4594 84.97 D 39403 D Ordinary Shares 2021-03-30 4 S 0 2986 85.88 D 36417 D Ordinary Shares 2021-03-30 4 S 0 3517 86.87 D 32900 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.23 to $84.095 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.53 to $85.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.55 to $86.545 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.60 to $87.33 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Miles W. McHugh, Attorney-in-Fact 2021-03-31